Gilead stock

Featured Story

2 Reasons Why Gilead Stock Will Rebound 35% by Next Year

By Alex McGuire, Associate Editor, Money Morning • @AlexMcGuire92 - May 20, 2016

The Gilead stock price has seen a massive downturn lately.

Since last month, GILD stock has fallen nearly 20% to $82 a share.

But we see shares of the biotech giant heading sharply higher by next year for two big reasons...

Article Index

Gilead Stock Price Prediction Shows More Gains Ahead (NYSE: GILD)

By Diane Alter, Contributing Writer, Money Morning - November 3, 2015

Our Gilead stock price prediction shows gains ahead, even after Gilead Sciences Inc. (Nasdaq: GILD) shares have fallen more than 7% since the beginning of August.

You see, the Gilead stock price recently got caught up in a sell-off of biotech stocks as regulators continue to investigate companies for drug price gouging.

But the stock price's drop has only made GILD stock more attractive

Why Gilead (Nasdaq: GILD) Is Still A Biotech Stock to Buy

By Kyle Anderson, Associate Editor, Money Morning • @KyleAndersonMM - April 16, 2015

Gilead Sciences Inc. (Nasdaq: GILD) is facing criticism again this week for its highly priced Hepatitis C drug Sovaldi. The drug costs $1,000 per pill.

According to The Wall Street Journal, many states have restricted access to the drug, leaving some patients unable to afford the treatment.

But despite the criticism, Gilead (Nasdaq: GILD) stock remains one of the best biotech stocks to buy today. Here's why...

2015 Stock Picks: Biotech Surges Alongside Precious Metals

By Jim Bach, Associate Editor, Money Morning • @JimBach22 - January 23, 2015

Our 2015 stock picks show us two trends.

Precious metals are still surging. And now, biotech stocks are coming into 2015 hot.

Take a look at these exciting developments for our top stocks in 2015...

This Biotech Stock Winner Has Wall Street Fooled

By Michael A. Robinson, Defense + Tech Specialist, Money Morning • @Robinson_STI - December 2, 2014

Today I want to reintroduce you to a biotech stock that Wall Street has been pricing as though it were dead money.

This biotech company recently filed a stellar earnings report. But those earnings were slightly off analyst expectations, and the share price dipped.

But Wall Street's ignorance gives us an entry point the likes of which we probably won't see again for years...

Two of the Best Biotech Stocks to Buy Now

By Michael A. Robinson, Defense + Tech Specialist, Money Morning • @Robinson_STI - September 15, 2014

Since April 11, Gilead Sciences (Nasdaq: GILD) has scored peak gains of a 74.2% - or more than 175% annualized gains.

Some investors don't want to risk it all during a sell-off - but they still want to take advantage of the growth biotech stocks offer.

Here are two biotech stocks to buy – one appeals to risk takers and one to investors who favor a more conservative approach – and both offer plenty of upside potential…

Gilead (Nasdaq: GILD) Stock Outlook Even Better After Crushing Earnings

By Kyle Anderson, Associate Editor, Money Morning • @KyleAndersonMM - July 24, 2014

Gilead Sciences Inc. (Nasdaq: GILD) stock hit a 52-week high of $92.97 this morning (Thursday) after the company crushed earnings estimates last night. At that price, the stock was up 3% from yesterday's closing price.

Money Morning’s Defense and Tech Specialist Michael Robinson has been high on GILD stock for some time, and yesterday’s huge earnings beat comes as no surprise to Money Morning readers.

Here’s why this hot biotech stock is just getting started.